These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35659203)

  • 1. Corticosteroid therapy for nephrotic syndrome in children.
    Hahn D; Samuel SM; Willis NS; Craig JC; Hobson EM
    Cochrane Database Syst Rev; 2020 Aug; 2020(8):CD001533. PubMed ID: 35659203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid therapy for nephrotic syndrome in children.
    Hahn D; Samuel SM; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD001533. PubMed ID: 39171624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid therapy for nephrotic syndrome in children.
    Hahn D; Hodson EM; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD001533. PubMed ID: 25785660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
    Larkins NG; Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002290. PubMed ID: 32297308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for minimal change disease in adults with nephrotic syndrome.
    Azukaitis K; Palmer SC; Strippoli GF; Hodson EM
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD001537. PubMed ID: 35230699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM; Knight JF; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2004; (2):CD001533. PubMed ID: 15106158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM; Knight JF; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2003; (1):CD001533. PubMed ID: 12535410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM; Knight JF; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2001; (2):CD001533. PubMed ID: 11405997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2007 Oct; (4):CD001533. PubMed ID: 17943754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM; Knight JF; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2000; (4):CD001533. PubMed ID: 11034723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM; Knight JF; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001533. PubMed ID: 15674881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for preventing and treating kidney disease in IgA vasculitis.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD005128. PubMed ID: 36853224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for focal segmental glomerulosclerosis in adults.
    Hodson EM; Sinha A; Cooper TE
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
    Pravitsitthikul N; Willis NS; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2013 Oct; (10):CD002290. PubMed ID: 24166716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
    von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
    Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-corticosteroid treatment for nephrotic syndrome in children.
    Durkan A; Hodson E; Willis N; Craig J
    Cochrane Database Syst Rev; 2001; (4):CD002290. PubMed ID: 11687155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.